VCR ventracor limited

abc programme transcript

  1. 29 Posts.
    Ventracor Limited 126 Greville Street Chatswood NSW 2067 Australia
    T +61 2 9406 3100 F +61 2 9406 3101 W www.ventracor.com
    ABN 46 003 180 372
    Ventracor’s ‘Artificial Heart’ Receives National Recognition
    Sydney, 2 July 2004: Australian heart company Venrtracor Limited (ASX:
    VCR) today welcomed a current affairs item broadcast on national ABC TV
    Thursday evening referring to its VentrAssist™ artificial heart device and
    patients taking part in the pilot trial at The Alfred hospital in Melbourne.
    Ventracor Chief Executive Officer, Colin Sutton PhD, welcomed the ABC’s
    balanced and accurate coverage of it’s VentrAssist™ system which is poised
    to begin a wider clinical trial soon.
    The ABC TV report was broadcast to an estimated national audience of one
    million people. A transcript is provided.
    Ventracor Limited can not publish patient names in line with clinical trial
    regulations and The Privacy Act.
    Transcript ABC TV 7:30 Report Thursday 1 July 2004
    PRESENTER KERRY O'BRIEN: In a Melbourne hospital tonight, a man once
    on the verge of death due to a severe heart condition is now sitting up and
    hopefully taking the first steps towards recovery.
    He is the sixth person to receive an Australian-made artificial heart, under a
    pilot trial.
    The three decade long race to develop a workable artificial heart has been
    dogged by flawed mechanics and infection.
    But doctors believe this new device can lengthen the lives of thousands of
    patients around the world who otherwise would have no hope.
    Mary Gearin spoke to three recipients of what's billed as world beating, heart
    beating technology..Ventracor Limited 126 Greville Street Chatswood NSW 2067 Australia
    T +61 2 9406 3100 F +61 2 9406 3101 W www.ventracor.com
    ABN 46 003 180 372
    REPORTER MARY GEARIN: This man has no pulse. It was taken away by
    the technology that saved his life. That whirring you hear is
    (PATIENT NAME)‘s heart.
    PATIENT: I call it me washing machine. If I put my hand there, any time I can
    feel it going. You look nice enough to be able to put your hand on me if you
    want to feel my washing machine running.
    MARY GEARIN: (Laughs) That's quite an offer.
    PATIENT: Well, there you go. You won't get many like that.
    MARY GEARIN: In fact, you can get only four offers like that worldwide.
    As part of a trial at Melbourne's Alfred Hospital, (PATIENT NAME) and three
    other patients are living with artificial hearts based on a continuously spinning
    rotor.
    ASSOCIATE PROFESSOR DAVID KAYE, ALFRED HOSPITAL: So the
    pump is continuously pumping blood, unlike the heart, of course, which fills
    and empties and, as such, creates a pulse.
    So it is an interesting phenomenon. When you first see these patients, you go
    to feel a pulse and, of course, they don't have one but here they are sitting up,
    talking to you, feeling fine.
    MARY GEARIN: Seventy-four-year-old (PATIENT NAME) says in a way he's
    just celebrated his first birthday.
    It was just a year and two days ago that he received his new heart after more
    than a decade of severe heart problems.
    How do you compare your life before with now?
    PATIENT: You can't really. It's like chocolate and toffee.
    MARY GEARIN: The only thing slowing (PATIENT NAME) down now is a
    backpack powering his mechanical heart.
    It's driven by a rotor suspended in a magnetic field, receiving blood from his
    own heart, returning it to the aorta.
    The pump is inserted just below the left side of the rib cage, with a cable
    coming out the patient's right side.
    It connects to batteries that beep before needing to be changed every four
    hours, or the patient can be plugged straight into the mains, which has led to
    at least one odd restaurant scene for (PATIENT NAME), another recipient,
    and his wife..Ventracor Limited 126 Greville Street Chatswood NSW 2067 Australia
    T +61 2 9406 3100 F +61 2 9406 3101 W www.ventracor.com
    ABN 46 003 180 372
    PATIENT: So, we walked in and calmly asked the waitress, "Could we be
    seated near a power plug? And there was a somewhat astonished look on her
    face.”
    MARY GEARIN: The VentrAssist is called a third-generation device, differing
    from earlier, unwieldy models that agitate the blood more quickly and have
    wearable parts, typically causing three major problems.
    ASSOCIATE PROFESSOR DON ESMORE, ALFRED HOSPITAL: They are,
    basically, mechanical failure, blood clots forming in the pump or the pump
    stopping due to blood clots clogging the mechanism or the device gets
    infected and the patients get major complications from that, which can't be
    curable because it's an implanted system.
    And we really have not had any of those.
    MARY GEARIN: How long do you think it can live?
    ASSOCIATE PROFESSOR DAVID KAYE: That's a good question.
    Certainly in experimental tests the device has been running continuously for
    over two years.
    MARY GEARIN: (PATIENT NAME), (PATIENT NAME), (PATIENT NAME)
    and another patient implanted just last week are the success stories for this
    trial. But two others died, according to the doctors for reasons unrelated to the
    device.
    After the second death in March, shares in the manufacturer Ventracor fell
    sharply, but the hospital resumed the trial after an internal review of its
    processes.
    ASSOCIATE PROFESSOR DAVID KAYE: Look, I think we're certainly
    disappointed and sad that those patients didn't make it through.
    I think, unfortunately, one has to recognise that for patients who are gravely ill
    coming into any device that this is not a cure all.
    MARY GEARIN: The company - and the technology - will get a further chance
    to prove their worth in a trial starting this month in other hospitals around
    Australia, as well as in NZ and the UK.
    The trials will continue to target elderly patients who would have no prospect
    of receiving heart transplants, but who could then perhaps live on this device
    for some years.
    PATIENT: Fantastic - because without it, I'm not here.
    MARY GEARIN: Each device is still handmade at a cost of up to $100,000,
    and Associate Professor Esmore acknowledges some may see this as a
    luxury therapy..Ventracor Limited 126 Greville Street Chatswood NSW 2067 Australia
    T +61 2 9406 3100 F +61 2 9406 3101 W www.ventracor.com
    ABN 46 003 180 372
    ASSOCIATE PROFESSOR DON ESMORE: But I think for the individual
    who's 60, 70 years of age and otherwise well, and has end stage heart
    disease, and they can have a device like this implanted, either for a small or
    no cost, that gives them a chance at quality and duration of survival, I think it's
    very, very hard for us, as individuals, to withhold that therapy from them
    merely based on cost.
    MARY GEARIN: For the ladies who are there to change the batteries and
    take over any duties with power tools, all the money and work is worth it.
    PATIENT’S WIFE: I'm extremely grateful. Yes, grateful.
    PATIENT’S WIFE: We all said to (PATIENT NAME), "It is up to you. It is your
    life at stake," and he said, "I want to do it."
    So we took the gamble and it has been a wonderful gamble.
    PATIENT’S WIFE: It has been great. It's, I mean, he is still here.
    MARY GEARIN: The surgery has also allowed (PATIENT NAME) to live to his
    50th wedding anniversary a couple of months ago with the woman he calls
    "his little girl", Irene.
    And he says his four kids are proud he's helping medical science.
    PATIENT: I don't think they were too unhappy with me before, but when I had
    this done for other people they said, "We are so damned proud of you. So I
    thought, well, there you go, hey?”
    KERRY O'BRIEN: Spoken like an Aussie.
    For more information, please contact:
    Andrew Geddes
    Manager, Investor Relations
    Ventracor Limited
    02 9406 3086
 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.